Baseline characteristics of intravenous thrombolysis-treated patients according to renal function
| Characteristics | Tenecteplase | Alteplase | ||||||
| eGFR≥90 mL/min/1.73 m2 (n=465) | eGFR 60–89 mL/min/1.73 m2 (n=195) | eGFR<60 mL/min/1.73 m2 (n=45) | P value | eGFR≥90 mL/min/1.73 m2 (n=486) | eGFR 60–89 mL/min/1.73 m2 (n=171) | eGFR<60 mL/min/1.73 m2 (n=50) | P value | |
| Age, years | 62.36±10.54 | 71.12±10.37 | 73.82±11.80 | <0.001 | 62.11±10.34 | 69.56±9.74 | 75.56±11.87 | <0.001 |
| Females, n (%) | 130 (27.96) | 64 (32.82) | 22 (48.89) | 0.01 | 144 (29.63) | 64 (37.43) | 20 (40.00) | 0.08 |
| Body mass index, kg/m2 | 23.99±3.45 | 23.65±3.63 | 22.50±3.77 | 0.02 | 24.31±3.44 | 23.95±3.58 | 23.46±3.39 | 0.18 |
| National Institutes of Health Stroke Scale scale | 7.0 (5.0 to 10.0) | 7.0 (5.0 to 10.0) | 7.0 (5.0 to 12.0) | 0.76 | 7.0 (6.0 to 10.0) | 8.0 (6.0 to 11.0) | 6.0 (5.0 to 10.0) | 0.12 |
| Medical history | ||||||||
| Hypertension, n (%) | 315 (67.74) | 152 (77.95) | 39 (86.67) | 0.007 | 339 (69.75) | 128 (74.85) | 45 (90.00) | 0.007 |
| Diabetes, n (%) | 110 (23.66) | 47 (24.10) | 13 (28.89) | 0.74 | 137 (28.19) | 55 (32.16) | 15 (30.00) | 0.61 |
| Hyperlipidaemia, n (%) | 90 (19.35) | 34 (17.44) | 5 (11.11) | 0.37 | 114 (23.46) | 35 (20.47) | 11 (22.00) | 0.72 |
| Coronary heart disease, n (%) | 97 (20.86) | 53 (27.18) | 16 (35.56) | 0.03 | 102 (20.99) | 46 (26.90) | 18 (36.00) | 0.03 |
| Arrhythmia, n (%) | 67 (14.41) | 55 (28.21) | 13 (28.89) | <0.001 | 79 (16.26) | 48 (28.07) | 19 (38.00) | <0.001 |
| Current smoker, n (%) | 196 (42.24) | 54 (27.69) | 14 (31.11) | 0.004 | 213 (43.92) | 53 (30.99) | 10 (20.00) | <0.001 |
| History of medication use, n (%) | ||||||||
| Antiplatelet agents | 53 (11.40) | 31 (15.90) | 6 (13.33) | 0.28 | 55 (11.32) | 23 (13.45) | 14 (28.00) | 0.004 |
| Anticoagulant agents | 1 (0.22) | 4 (2.05) | 0 (0.00) | 0.03 | 3 (0.62) | 4 (2.34) | 0 (0.00) | 0.11 |
| Lipid-lowering drugs | 32 (6.88) | 28 (14.36) | 7 (15.56) | 0.004 | 34 (7.00) | 17 (9.94) | 9 (18.00) | 0.02 |
| Hypoglycaemic drugs | 74 (15.91) | 26 (13.33) | 7 (15.56) | 0.70 | 77 (15.84) | 34 (19.88) | 7 (14.00) | 0.41 |
| Antihypertensive drugs | 181 (38.92) | 94 (48.21) | 19 (42.22) | 0.09 | 203 (41.77) | 84 (49.12) | 31 (62.00) | 0.01 |
| Modified Rankin Scale score before stroke | 0.34 | 0.07 | ||||||
| 0 | 421 (90.54) | 169 (86.67) | 40 (88.89) | 438 (90.12) | 155 (90.64) | 40 (80.00) | ||
| 1 | 44 (9.46) | 26 (13.33) | 5 (11.11) | 48 (9.88) | 16 (9.36) | 10 (20.00) | ||
| Onset-to-needle time, hours | 179.05±55.96 | 176.65±55.68 | 163.02±45.55 | 0.13 | 182.80±56.72 | 171.17±56.95 | 181.10±58.53 | 0.09 |
| Bridging thrombectomy, n% | 19 (4.09) | 6 (3.08) | 2 (4.44) | 0.81 | 16 (3.29) | 8 (4.68) | 0 (0.00) | 0.27 |
| eGFR, mL/min/1.73 m2 | 107.93±11.32 | 78.19±7.92 | 46.58±12.53 | <0.001 | 107.30±10.27 | 76.90±9.06 | 46.51±10.74 | <0.001 |
| Serum creatinine, umol/L | 63.12±11.21 | 87.17±13.57 | 139.91±67.71 | <0.001 | 63.79±11.94 | 88.42±14.67 | 135.95±46.45 | <0.001 |
Data are expressed as mean ± SD, median (IQR) or n (%).
eGFR, estimated glomerular filtration rate.